October 9, 2019 / 1:20 PM / 8 days ago

BRIEF-Dermira Says Initiation Of First Phase 3 Clinical Study In Lebrikizumab Phase 3 Development Program Triggers A $7.5 Mln Milestone Payment By Almirall

Oct 9 (Reuters) - Dermira Inc:

* DERMIRA - INITIATION OF FIRST PHASE 3 CLINICAL STUDY IN LEBRIKIZUMAB PHASE 3 DEVELOPMENT PROGRAM TRIGGERS A $7.5 MILLION MILESTONE PAYMENT BY ALMIRALL

* DERMIRA - INITIATION OF LEBRIKIZUMAB PHASE 3 CLINICAL STUDY ALSO TRIGGERS A $20.0 MILLION MILESTONE PAYMENT BY DERMIRA TO F. HOFFMANN-LA ROCHE LTD Source text: (bit.ly/2ICZUvg) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below